Healthcare Industry News: Acute Coronary Syndrome
News Release - January 10, 2006
Dade Behring Grants Sublicense to Abbott for the Use of Placental Growth Factor (PlGF) for the Diagnosis of Cardiovascular DiseasesDEERFIELD, Ill.--(HSMN NewsFeed)--Jan. 10, 2006--Dade Behring Inc.(NASDAQ:DADE ), the world's largest company solely dedicated to clinical diagnostics, announced today that they have granted a non-exclusive sublicense to Abbott for the worldwide rights for the use of the emerging cardiac marker placental growth factor (PlGF), for further development of tests for the diagnosis and prognosis of cardiovascular diseases. Studies show that levels of PlGF may be useful in the prognosis of Acute Coronary Syndrome (ACS)(1), a heart condition that impacts millions of people worldwide(2). By offering rights to this emerging cardiac marker to Abbott, its availability can be expanded to a larger spectrum of global health care providers. No additional terms of the agreement were disclosed.
"As a leader in the cardiac diagnostic market, we feel it is extremely important to make emerging cardiac markers such as PlGF available to health care providers throughout the world," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "By entering into this agreement, we reaffirm our commitment to share the availability of emerging diagnostic markers to ensure patients' access to the best care available."
This agreement provides the basis for Abbott to independently develop assays for use on its instruments. Such tests, when available, may provide physicians with valuable information for the prognosis following cardiovascular events, and prevention of such events in healthy persons. In addition, the development of these tests may provide valuable information for diagnosis, prognosis, and a more targeted treatment for patients with ACS.
"This agreement will help further expand the menu of cardiac-health related assays available from Abbott," said William Brown, Ph.D., vice president, diagnostic assays and system development, Abbott Diagnostics. "We look forward to beginning our work on developing and introducing this and other important new products in this area."
The rights of the agreement are specific to an invention of Professor Zeiher and his group from the University of Frankfurt, Germany. Professor Zeiher is a cardiologist known for leading successful advanced medical research.
About the role of emerging markers in the Acute Coronary Syndrome (ACS)
ACS describes the continuum from unstable angina to acute myocardial infarction. For the successful and efficient management of this health threat, an early and accurate diagnosis of patients is a prerequisite, which helps physicians provide the patient with an optimal treatment. The emerging marker placental growth factor (PlGF) has been shown in studies to provide valuable information for the diagnosis and prognosis of ACS.
Originally identified in the placenta, PlGF is now considered to be a primary instigator of atherosclerotic plaque instability. It has also been recognized as an independent and powerful predictor for adverse outcome for patients with known or suspected ACS. PlGF may provide independent, complementary information to routine markers such as cardiac troponin I and hsCRP, among others.
About Dade Behring
With 2004 revenues of nearly $1.6 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the internet at www.dadebehring.com.
(1) Heeschen, C., S. Dimmeler, et al. (2004). "Prognostic value of placental growth factor in patients with acute chest pain." JAMA 291 (4): 435-41.
(2) American Heart Association (2005). www.americanheart.org.
Source: Dade Behring
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.